Form 4: Organogenesis CCO Exercises Options Before Expiry

Chief Commercial Officer Brian Grow exercised options for 958 shares of Class A Common Stock shortly before their expiration date.

Summary

• Brian Grow, the Chief Commercial Officer, exercised 958 stock options on January 10, 2025.
• The options were exercised at a price of 1.24 dollars per share.
• Following this transaction, Brian Grow directly owns 900,682 shares of Class A Common Stock.
• The options exercised were 100 percent vested and were set to expire on January 12, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a small, non-market transaction required to prevent the expiration of vested options.

Positives

• The executive maintained the acquired shares rather than selling them immediately, increasing his total direct ownership.
• The exercise price of 1.24 dollars represents a low-cost acquisition of equity for the reporting person.
• The reporting person continues to hold a significant stake in the company with over 900,000 shares.

Negatives

• The transaction volume of 958 shares is negligible, representing approximately 0.1 percent of the executive's total holdings.
• The exercise appears to be a 'use it or lose it' scenario driven by the impending expiration date rather than a strategic market timing signal.

Risks

• No specific business or financial risks are disclosed in this ownership change statement.

Future Outlook

The filing does not provide specific forward-looking guidance or financial projections.

Management Comments

• The shares subject to the option are 100 percent fully vested and exercisable.

Industry Context

StockSavvy.ai notes that this is a routine administrative exercise of expiring options, which is common among executives in the regenerative medicine and biotech sectors to preserve vested compensation.

Comparison to Industry Standards

• The exercise of options within 48 hours of expiration is a standard practice across the Nasdaq Biotechnology Index to avoid the forfeiture of equity awards.
• The executive's high level of direct ownership (900k+ shares) is consistent with long-tenured C-suite officers in mid-cap medical technology companies.

Related Party Transactions

• The reporting person exercised options granted by the issuer as part of an equity incentive plan.

Stakeholder Impact

• Minimal impact on shareholders due to the very low number of shares issued (958 shares).
• Demonstrates continued alignment of the Chief Commercial Officer with long-term equity ownership.

Next Steps

• No future actions or milestones are specified in this filing.

Key Dates

Recommendation

This filing represents a routine administrative matter with no material impact on the company's financial health or strategic direction. Investors should maintain their current positions pending more substantive financial disclosures.

Keywords

Organogenesis Holdings Inc., ORGO, Insider Trading, Stock Options, Executive Compensation, Brian Grow, Chief Commercial Officer, Form 4